Targovax (TRVX) Småprat

[Martins]

Bare småpenger, snakkes på 9-12kr Kanskje horden som hoppet inn i PCIB i går kom på at resultatene allerede er ute og at Targo sine resultater kommer straks

[tubist92]

Godt vi er nede på rødfargen og det vante gamle igjen… grønn farge er teit…

[Martins]

Sant, føltes nesten ikke ut som Targo lenger.

[ufo]

den kommer med et

[aborum]

Er i markedet for flere aktier, så det er med blandede følelser, man følger kursen op 6,5% og tilbage i rødt.

Citi reducerer vel helt til 0?

[TekBot]

08/05-2019 07:09:57: (TRVX) Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma

· The trial is now fully recruited, with a total of 31 patients enrolled
· Data read-outs expected around New Year

…

Vis børsmeldingen

Oslo, Norway, 8 May 2019 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, today announces that it has completed patient enrollment in the phase
Ib/II trial of ONCOS-102 in combination with chemotherapy in unresectable
malignant pleural mesothelioma (MPM).

The trial consists of a phase Ib safety lead-in part followed by a randomized,
open label phase II part, assessing the combination of ONCOS-102 and standard of
care (SoC) chemotherapy (pemetrexed and cisplatin) vs SoC chemotherapy alone in
first or second/third line patients with unresectable MPM. In May 2018, Targovax
reported no safety issues, strong innate and adaptive immune activation and 50%
disease control rate (DCR) for the six patients in the phase Ib safety lead-in
cohort - see link to press release here (https://www.targovax.com/en/targovax
-announces-early-signal-of-efficacy-in-oncos-102-trial-in-mesothelioma/).

The enrollment of 25 patients into the randomized phase II part of the trial has
now been completed, with a total of 31 patients on the trial who will be
evaluated for safety, immune response and efficacy. There are 20 patients in the
experimental arm combining ONCOS-102 with chemotherapy and eleven patients in
the chemotherapy only control group. The patients in the part I safety cohort
form part of the experimental arm.

The aim of the trial is to assess safety and tolerability, immunological
activation and 6-month overall response rate (ORR) of the combination of ONCOS
-102 and SoC chemotherapy compared to SoC chemotherapy alone. Data read out is
expected around New Year.

Magnus Jäderberg, CMO of Targovax, said: “We are very pleased to have completed
enrollment of our mesothelioma trial. ONCOS-102 is currently the most clinically
advanced oncolytic virus in this difficult to treat cancer, and therefore a high
priority for us. The randomized ORR and immune data from this study will
indicate whether the ONCOS-102 and chemotherapy combination gives patients a
benefit over chemotherapy. The clinical and immune data will guide the further
development of ONCOS-102 in mesothelioma.”
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
(Targovax@fticonsulting.com)
About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102’s targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized phase
II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma,
is expected to produce important proof-of-concept immune activation data in
heavily pre-treated patients.

Targovax is also developing a neoantigen cancer vaccine targeting tumors with
oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program
has shown strong RAS-specific immune activation and a signal of clinical
efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next
generation product candidate, TG02 is currently tested in a phase I trial in
colorectal cancer, both as monotherapy and in combination with Keytruda (an anti
-PD1 check point inhibitor).

http://www.netfonds.no/quotes/release.php?id=20190508.OBI.20190508S22

[BioMed]

08/05-2019 07:09:57: (TRVX) Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma

The trial is now fully recruited, with a total of 31 patients enrolled

Data read-outs expected around New Year

[aborum]

Potentielt registreringsstudie?

En stærk melding på aborums fødselsdag

[InVivo]

Shit, det gikk fort!

En stærk melding på aborums fødselsdag

Gratulerer med dagen!

[InVivo]

Under 2 måneder til vi får nytt herfra:

[Whatsthat]

Data read-outs expected around New Year

kanskje vi får data før guidingen som var H1 2020 før det forhåpentligvis peritoneal og prostata og staks litt melanoma… 2019 kan bli stort for oncos-102…

[dro]

What does It means ?

[Whatsthat]

Har du store forventninger til denne? Er det ikke “bare” data for 3 siste pasienter på “feil” dose?

[Ramsess]

Gratulere til deg og til oss andre!

[BioMed]

TRVX:ONCOS-102 FULLSTENDIG REKRUTTERT MED 31 PASIENTER

07:24
Oslo (TDN Direkt): Oncos-102-studien er nå fullstendig rekruttert med til sammen 31 pasienter.

Det skriver selskapet i en melding onsdag.

25 pasienter er innrullert i en randomisert fase 2-del av studien, mens til sammen 31 pasienter vil vurderes for sikkerhet, immunrespons og effekt.

[InVivo]

What does It means ?

[dro]

Doubled rainbow it is

[Oilimp]

Amerikanere er sinnsykt irriterende med denne evinnelige “wohoooo!!!” greia deres for alt mulig!
A rainbow? Woo-fokkin hoo…

[Markusf]

Trippel rainbow vel å merke …

[Chrysler300C]

nydelig

Får håpe det pøses ut med Emi aksjer idag da Flott og få de ut før TG meldinga